肯尼亚随机疫苗田间试验:牛对角马相关恶性卡他热的保护效果
在肯尼亚进行的一项随机安慰剂对照田间试验纳入146头牛,评估基于减毒AlHV-1 C500株的疫苗预防致命性角马相关恶性卡他热(WA-MCF)的效果。疫苗组和对照组分别有5.6%和29.2%的牛死于WA-MCF(p<0.001),疫苗效力为80.6%(95%CI 46.5-93.0%)。该疫苗安全且可能有效,对边缘化养牛社区有重要意义。
要点
- 减毒AlHV-1 C500疫苗在自然角马攻击下显示80.6%的效力。
- 疫苗组WA-MCF死亡率5.6%,显著低于对照组的29.2%。
- 疫苗组所有牛均产生血清学应答,不良反应少(n=4)。
核心结论
- AlHV-1 C500疫苗安全且对预防牛致命性WA-MCF有效,效力为80.6%(95%CI 46.5-93.0%)。
研究设计与样本
- 2016年在肯尼亚Kapiti Plains Ranch Ltd进行的随机安慰剂对照田间试验,共纳入146头牛。
- 牛按品种和年龄分层后随机分组,分别接种疫苗或含Emulsigen®的培养基,间隔一个月初免和加强。
主要发现
- 疫苗组所有牛通过间接ELISA均产生对AlHV-1的血清学应答。
- 所有WA-MCF病牛经PCR确认感染AlHV-1,23例有典型组织病理学表现。
- 仅观察到少量不良反应(n=4)。
关键数值与推荐
- WA-MCF年发病率在角马流行区可达10%。
- 疫苗效力为80.6%(95%CI 46.5-93.0%)。
临床怎么用
- 在角马流行区,可考虑使用AlHV-1 C500疫苗接种牛以预防致命性WA-MCF。
- 接种后需监测血清学应答,但自然攻击下仍需观察临床发病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Wildebeest-associated malignant catarrhal fever (WA-MCF), a fatal disease of cattle caused by alcelaphine herpesvirus 1 (AlHV-1), is one of the most important seasonal diseases of cattle in wildebeest endemic areas, with annual incidence reaching 10%. Here we report efficacy of over 80% for a vaccine based on the attenuated AlHV-1 C500 strain, in preventing fatal WA-MCF in cattle exposed to natural wildebeest challenge. The study was conducted at Kapiti Plains Ranch Ltd, south-east of Nairobi, Kenya. In 2016, 146 cattle were selected for a randomised placebo-controlled trial. Cattle were stratified according to breed and age and randomly assigned to groups given vaccine or culture medium mixed with Emulsigen®. Cattle received prime and boost inoculations one month apart and few adverse reactions (n = 4) were observed. Indirect ELISA demonstrated that all cattle in the vaccine group developed a serological response to AlHV-1. The study herd was grazed with wildebeest from one month after booster vaccination. Three cattle, two that received vaccine and one control, succumbed to conditions unrelated to WA-MCF before the study ended. Twenty-five cattle succumbed to WA-MCF; four of the remaining 71 cattle in the vaccine group (5.6%) and 21 of the remaining 72 control cattle (29.2%; χ2 = 13.6, df = 1, p < 0.001). All of the WA-MCF affected cattle were confirmed by PCR to be infected with AlHV-1 and in 23 cases exhibited histopathology typical of WA-MCF. Vaccine efficacy was determined to be 80.6% (95% CI 46.5-93.0%). Hence, the AlHV-1 C500 vaccine is a safe and potentially effective novel method for controlling WA-MCF in cattle. The implementation of this vaccine may have significant impacts on marginalised cattle keeping communities.
引用
- Cook E, Russell G, Grant D, et al. A randomised vaccine field trial in Kenya demonstrates protection against wildebeest-associated malignant catarrhal fever in cattle. Vaccine. 2019. PMID: 31473000. doi:10.1016/j.vaccine.2019.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。